keyword
MENU ▼
Read by QxMD icon Read
search

Glimepiride

keyword
https://www.readbyqxmd.com/read/29334906/rationale-and-design-of-the-carolina%C3%A2-cognition-substudy-a-randomised-controlled-trial-on-cognitive-outcomes-of-linagliptin-versus-glimepiride-in-patients-with-type-2-diabetes-mellitus
#1
Geert Jan Biessels, Jolien Janssen, Esther van den Berg, Bernard Zinman, Mark A Espeland, Michaela Mattheus, Odd Erik Johansen
BACKGROUND: Type 2 diabetes mellitus is associated with cognitive dysfunction and an increased risk of dementia. Linagliptin is a glucose-lowering agent of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class that is of particular interest for the prevention of accelerated cognitive decline, because it may potentially benefit the brain through pleiotropic effects, beyond glucose lowering. This paper presents the design of a study that aims to establish if linagliptin is superior to the sulfonylurea glimepiride in the prevention of accelerated cognitive decline in patients with type 2 diabetes mellitus...
January 15, 2018: BMC Neurology
https://www.readbyqxmd.com/read/29319909/inhibitory-effects-of-sulfonylureas-and-non-steroidal-anti-inflammatory-drugs-on-in-vitro-metabolism-of-canagliflozin-in-human-liver-microsomes
#2
Sara Algeelani, Dalal Alkhelb, David J Greenblatt
Canagliflozin, used to treat type 2 diabetes mellitus (T2DM), is commonly co-administered with sulfonylureas. The objective of the present study was to evaluate the possible inhibitory effect of sulfonylureas and non-steroidal anti-inflammatory drugs (NSAIDs) on canagliflozin metabolism in vitro. Three sulfonylurea derivatives were evaluated as inhibitors: chlorpropamide, glimepiride, and gliclazide. Two other NSAIDs were used as positive control inhibitors: niflumic acid and diclofenac. The rate of formation of canagliflozin metabolites was determined by HPLC analysis of vitro incubations of canagliflozin as a substrate with and without inhibitors, using human liver microsomes (HLMs)...
January 10, 2018: Biopharmaceutics & Drug Disposition
https://www.readbyqxmd.com/read/29285488/comparative-effectiveness-and-safety-of-empagliflozin-on-cardiovascular-mortality-and-morbidity-in-adults-with-type-2-diabetes
#3
Wilbert S Aronow, Tatyana A Shamliyan
Background: Based on a single placebo-controlled randomized clinical trial, empagliflozin is licensed to reduce cardiovascular death in diabetes and comorbid cardiovascular disease. Methods: We examined the comparative effectiveness of empagliflozin on mortality and cardiovascular morbidity in type 2 diabetes. We conducted random-effects direct frequentist meta-analyses of aggregate data and appraised the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology...
December 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/29282633/ertugliflozin-compared-with-glimepiride-in-patients-with-type-2-diabetes-mellitus-inadequately-controlled-on-metformin-the-vertis-su-randomized-study
#4
Priscilla Hollander, Jie Liu, Julie Hill, Jeremy Johnson, Zhi Wei Jiang, Gregory Golm, Susan Huyck, Steven G Terra, James P Mancuso, Samuel S Engel, Brett Lauring
INTRODUCTION: This study assessed the safety and efficacy of ertugliflozin (an oral sodium-glucose cotransporter 2 inhibitor) vs. glimepiride in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin. METHODS: This phase III, double-blind, non-inferiority study (NCT01999218) randomized patients with HbA1c ≥ 7.0% and ≤ 9.0% on stable metformin ≥ 1500 mg/day 1:1:1 to ertugliflozin 15 or 5 mg once-daily (QD), or glimepiride (titrated from 1 mg QD)...
December 27, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29184539/effects-on-subclinical-heart-failure-in-type-2-diabetic-subjects-on-liraglutide-treatment-vs-glimepiride-both-in-combination-with-metformin-a-randomized-open-parallel-group-study
#5
Thomas Nyström, Irene Padro Santos, Fredric Hedberg, Johan Wardell, Nils Witt, Yang Cao, Leif Bojö, Bo Nilsson, Johan Jendle
Objective: We aimed to investigate the effect of liraglutide treatment on heart function in type 2 diabetes (T2D) patients with subclinical heart failure. Methods: Randomized open parallel-group trial. 62 T2D patients (45 male) with subclinical heart failure were randomized to either once daily liraglutide 1.8 mg, or glimepiride 4 mg, both add on to metformin 1 g twice a day. Mitral annular systolic (s') and early diastolic (e') velocities were measured at rest and during bicycle ergometer exercise, using tissue Doppler echocardiography...
2017: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29180715/a-plga-reinforced-peg-in-situ-gel-formulation-for-improved-sustainability-of-hypoglycaemic-activity-of-glimepiride-in-streptozotocin-induced-diabetic-rats
#6
Osama A A Ahmed, Khalid M El-Say, Abdulrahman M Alahdal
Glimepiride (GMD) is a third-generation sulfonylurea derivative and one of the top three most-prescribed oral antidiabetic drugs. The need for a depot formulation exists, and a safe and effective antidiabetic therapy is the goal of this study. The aims were to design a depot in situ gel (ISG) formulation and investigate the main factors that control the initial burst and sustain the GMD effect using the Box-Behnken design. The studied factors were polymer percent (X1), plasticizer percent (X2) and benzyl benzoate percent in N-methyl-2-pyrrolidone (X3)...
November 27, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29171937/incidence-rate-and-patient-characteristics-of-severe-hypoglycemia-in-treated-type-2-diabetes-mellitus-patients-in-japan-retrospective-dpc-database-analysis
#7
Yuika Ikeda, Takekazu Kubo, Eisei Oda, Machiko Abe, Shigeru Tokita
AIMS: To evaluate the incidence rate of and identify factors associated with severe hypoglycemic episodes in patients with treated T2DM. METHODS: Using Diagnosis Procedure Combination (DPC) hospital-based medical database, we performed a retrospective cohort study to assess the incidence rate of severe hypoglycemia in treated T2DM patients. We evaluated the associations between severe hypoglycemia and age, sex, complications and current use of insulin or sulfonylurea (SU) in a nested case control study...
November 24, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/29123848/a-case-of-type-2-diabetes-mellitus-with-metformin-associated-lactic-acidosis-initially-presenting-the-appearance-of-a-sulfonylurea-related-hypoglycemic-attack
#8
Kota Nishihama, Kanako Maki, Yuko Okano, Rei Hashimoto, Yasuhiro Hotta, Mei Uemura, Taro Yasuma, Toshinari Suzuki, Toyomi Hayashi, Eiji Ishikawa, Yutaka Yano, Esteban C Gabazza, Masaaki Ito, Yoshiyuki Takei
Case: A 64-year-old Japanese woman with diabetes mellitus was admitted for hypoglycemia. Her diabetes had been under good control with glimepiride, voglibose, exenatide, and metformin for a few years. Although overt proteinuria was observed, the serum creatinine values were within normal range during the routine outpatient follow-up. Hypoglycemic attack caused by glimepiride and loss of appetite by urinary tract infection were diagnosed. Then, metformin-associated lactic acidosis with acute renal failure caused by dehydration was detected...
January 2017: Acute Medicine & Surgery
https://www.readbyqxmd.com/read/29110647/a-randomized-placebo-controlled-clinical-trial-evaluating-the-safety-and-efficacy-of-the-once-weekly-dpp-4-inhibitor-omarigliptin-in-patients-with-type-2-diabetes-mellitus-inadequately-controlled-by-glimepiride-and-metformin
#9
Seung-Hwan Lee, Ira Gantz, Elizabeth Round, Melanie Latham, Edward A O'Neill, Paulette Ceesay, Shailaja Suryawanshi, Keith D Kaufman, Samuel S Engel, Eseng Lai
BACKGROUND: Type 2 diabetes (T2D) is a progressive disease that often requires a patient to use multiple antihyperglycemic agents to achieve glycemic control with disease progression. Omarigliptin is a once-weekly dipeptidyl peptidase-4 inhibitor. The purpose of this trial was to assess the efficacy and safety of adding omarigliptin to the treatment regimen of patients with T2D inadequately controlled by dual therapy with metformin and glimepiride. METHODS: Patients with T2D and HbA1c ≥7...
November 6, 2017: BMC Endocrine Disorders
https://www.readbyqxmd.com/read/29108130/comparative-risk-of-serious-hypoglycemia-with-oral-antidiabetic-monotherapy-a-retrospective-cohort-study
#10
Charles E Leonard, Xu Han, Colleen M Brensinger, Warren B Bilker, Serena Cardillo, James H Flory, Sean Hennessy
PURPOSE: To examine and compare risks of serious hypoglycemia among antidiabetic monotherapy-treated adults receiving metformin, a sulfonylurea, a meglitinide, or a thiazolidinedione. METHODS: We performed a retrospective cohort study of apparently new users of monotherapy with metformin, glimepiride, glipizide, glyburide, pioglitazone, rosiglitazone, nateglinide, or repaglinide within a dataset of Medicaid beneficiaries from California, Florida, New York, Ohio, and Pennsylvania...
November 6, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/29069819/comparison-of-twelve-single-drug-regimens-for-the-treatment-of-type-2-diabetes-mellitus
#11
Shao-Lian Wang, Wen-Bin Dong, Xiao-Lin Dong, Wen-Min Zhu, Fang-Fang Wang, Fang Han, Xin Yan
We performed a network meta-analysis to compare the efficacy of 12 single-drug regimens (Glibenclamide, Glimepiride, Pioglitazone, Rosiglitazone, Repaglinide, Metformin, Sitaglitin, Exenatide, Liraglutide, Acarbose, Benfluorex, and Glipizide) in the treatment of type 2 diabetes mellitus (T2DM). Fifteen relevant randomized controlled trials (RCTs) were included; direct and indirect evidence from these studies was combined, and weighted mean difference (WMD) and surface under the cumulative ranking curves (SUCRAs) were examined to evaluate the monotherapies...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28989886/comparative-evaluation-of-safety-and-efficacy-of-glimepiride-and-sitagliptin-in-combination-with-metformin-in-patients-with-type-2-diabetes-mellitus-indian-multicentric-randomized-trial-start-study
#12
T V Devarajan, S Venkataraman, Narayanan Kandasamy, Abraham Oomman, Hari Kishan Boorugu, S K P Karuppiah, Dushyant Balat
BACKGROUND AND OBJECTIVE: Modern sulfonylureas like glimepiride offer effective glycemic control with extrapancreatic benefits and good tolerability. The objective of the present study was to evaluate and compare safety and efficacy of glimepiride and sitagliptin in combination with metformin in patients with type 2 diabetes mellitus (T2DM). METHODS: In this open-label, randomized, comparative, multicenter study, a total of 305 T2DM patients who were either drug naïve or uncontrolled on metformin were randomized to glimepiride 1 or 2 mg/sustained-release metformin 1000 mg once daily (glimepiride group, n = 202) or sitagliptin 50 mg/metformin 500 mg twice daily (sitagliptin group, n = 103) for 12 weeks...
September 2017: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28982699/sitagliptin-100%C3%A2-mg-vs-glimepiride-1-3%C3%A2-mg-as-an-add-on-to-insulin-and-metformin-in-type-2-diabetes-swim
#13
Jothydev Kesavadev, Pradeep Babu Sadasivan Pillai, Arun Shankar, Gopika Krishnan, Sunitha Jothydev
OBJECTIVE: To compare the effect of sitagliptin (100 mg) vs glimepiride (1-3 mg) as add-on therapy in Indian type 2 diabetes (T2DM) patients on treatment with insulin and metformin (SWIM study). RESEARCH DESIGN AND METHODS: This 24-week, controlled, open-label study randomized T2DM patients (n = 440) receiving a stable dose of metformin and insulin combination therapy to sitagliptin (100 mg) or glimepiride (1-3 mg) as add-on therapy. Baseline HbA1c was ≥7...
November 2017: Endocrine Connections
https://www.readbyqxmd.com/read/28951669/a-rapid-hydrophilic-interaction-liquid-chromatographic-determination-of-glimepiride-in-pharmaceutical-formulations
#14
Si Zhou, Pengxiao Zuo, Yuegang Zuo, Yiwei Deng
Glimepiride is one of the most widely prescribed antidiabetic drugs and contains both hydrophobic and hydrophilic functional groups in its molecules, and thus could be analyzed by either reversed-phase high performance liquid chromatography (HPLC) or hydrophilic interaction liquid chromatography (HILIC). In the literature, however, only reversed-phase HPLC has been reported. In this study, a simple, rapid and accurate hydrophilic interaction liquid chromatographic method was developed for the determination of glimepiride in pharmaceutical formulations...
September 2017: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://www.readbyqxmd.com/read/28943269/ramadan-fasting-in-diabetes-exercise-in-problem-solving
#15
Banshi Saboo
AIM: Appropriate management of a diabetic patient with co-morbidities, who is willing to fast during Ramadan. Case presentation A 45 year old male patient with T2DM for 5 years, current A1c of 8.3% and other co-morbidities is currently treated with metformin 500mg BID and glimepiride 2mg. During the pre-Ramadan assessment, glimepiride 2mg was changed to extended release gliclazide 60mg. It resulted in an improvement in his glycemic and microalbuminuria status without any hypoglycemic episodes...
July 29, 2017: Diabetes & Metabolic Syndrome
https://www.readbyqxmd.com/read/28917544/effects-on-the-incidence-of-cardiovascular-events-of-the-addition-of-pioglitazone-versus-sulfonylureas-in-patients-with-type-2-diabetes-inadequately-controlled-with-metformin-tosca-it-a-randomised-multicentre-trial
#16
Olga Vaccaro, Maria Masulli, Antonio Nicolucci, Enzo Bonora, Stefano Del Prato, Aldo P Maggioni, Angela A Rivellese, Sebastiano Squatrito, Carlo B Giorda, Giorgio Sesti, Paolo Mocarelli, Giuseppe Lucisano, Michele Sacco, Stefano Signorini, Fabrizio Cappellini, Gabriele Perriello, Anna Carla Babini, Annunziata Lapolla, Giovanna Gregori, Carla Giordano, Laura Corsi, Raffaella Buzzetti, Gennaro Clemente, Graziano Di Cianni, Rossella Iannarelli, Renzo Cordera, Olga La Macchia, Chiara Zamboni, Cristiana Scaranna, Massimo Boemi, Ciro Iovine, Davide Lauro, Sergio Leotta, Elisabetta Dall'Aglio, Emanuela Cannarsa, Laura Tonutti, Giuseppe Pugliese, Antonio C Bossi, Roberto Anichini, Francesco Dotta, Antonino Di Benedetto, Giuseppe Citro, Daniela Antenucci, Lucia Ricci, Francesco Giorgino, Costanza Santini, Agostino Gnasso, Salvatore De Cosmo, Donatella Zavaroni, Monica Vedovato, Agostino Consoli, Maria Calabrese, Paolo di Bartolo, Paolo Fornengo, Gabriele Riccardi
BACKGROUND: The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. METHODS: TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50-75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2-3 g per day) were recruited from 57 diabetes clinics in Italy...
November 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28916379/carboxymethyl-fenugreek-galactomannan-gellan-gum-calcium-silicate-composite-beads-for-glimepiride-delivery
#17
Hriday Bera, Srilatha Mothe, Sabyasachi Maiti, Sridhar Vanga
Novel carboxymethyl fenugreek galactomannan (CFG)-gellan gum (GG)-calcium silicate (CS) composite beads were developed for controlled glimepiride (GLI) delivery. CFG having degree of carboxymethylation of 0.71 was synthesized and characterized by FTIR, DSC and XRD analyses. Subsequently, GLI-loaded hybrids were accomplished by ionotropic gelation technique employing Ca(+2)/Zn(+2)/Al(+3) ions as cross-linkers. All the formulations demonstrated excellent drug encapsulation efficiency (DEE, 48-97%) and sustained drug release behaviour (Q8h, 62-94%)...
September 12, 2017: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/28904527/cost-effectiveness-of-vildagliptin-versus-glimepiride-as-add-on-treatment-to-metformin-for-the-treatment-of-diabetes-mellitus-type-2-patients-in-greece
#18
Hara Kousoulakou, Magdalini Hatzikou, Varvara Baroutsou, John Yfantopoulos
OBJECTIVES: This study was designed to assess the cost-effectiveness of vildagliptin versus glimepiride as add-on to metformin in the management of type 2 diabetes mellitus (T2DM) patients in the Greek healthcare setting. METHODS: A cost-effectiveness model was designed, using MS Excel, to compare two treatment strategies. Strategy 1 consisted of first-line metformin, followed by metformin + vildagliptin in second-line, while strategy 2 consisted of first line metformin, followed by metformin + glimepiride in second line...
2017: Cost Effectiveness and Resource Allocation: C/E
https://www.readbyqxmd.com/read/28864828/-severe-atypical-ketoacidosis-due-to-sglt2-inhibitor-therapy-two-case-reports
#19
T G K Breuer, K Kampmann, A Wutzler, C Steinfort, W Uhl, W E Schmidt, J J Meier
Two female patients were admitted due to ketoacidosis. Serum glucose was moderately elevated. The patients exhibited abdominal and neurologic symptoms. Treatment consisted of metformin, insulin glargin and empagliflozin, as well as glimepiride, insulin detemir and empagliflozin, respectively. Treatment with intravenous fluid replacement, insulin, glucose, potassium and buffer solution led to a normalisation of pH and serum glucose levels. Our report describes two cases of atypical ketoacidosis with moderately elevated serum glucose during sodium-glucose co-transporter-2 (SGLT2) inhibitor therapy...
September 1, 2017: Der Internist
https://www.readbyqxmd.com/read/28864502/pharmacologic-differences-of-sulfonylureas-and-the-risk-of-adverse-cardiovascular-and-hypoglycemic-events
#20
Antonios Douros, Hui Yin, Oriana Hoi Yun Yu, Kristian B Filion, Laurent Azoulay, Samy Suissa
OBJECTIVE: Sulfonylureas have been associated with an increased risk of cardiovascular adverse events and hypoglycemia, but it is unclear if these risks vary with different agents. We assessed whether the risks of acute myocardial infarction, ischemic stroke, cardiovascular death, all-cause mortality, and severe hypoglycemia differ between sulfonylureas grouped according to pancreas specificity and duration of action. RESEARCH DESIGN AND METHODS: Using the U.K. Clinical Practice Research Datalink, linked with the Hospital Episodes Statistics and the Office for National Statistics databases, we conducted a cohort study among patients with type 2 diabetes initiating monotherapy with sulfonylureas between 1998 and 2013...
November 2017: Diabetes Care
keyword
keyword
32897
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"